Shanghai Kaibao Pharmaceutical - Asset Resilience Ratio
Shanghai Kaibao Pharmaceutical (300039) has an Asset Resilience Ratio of 17.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Shanghai Kaibao Pharmaceutical's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Shanghai Kaibao Pharmaceutical to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Kaibao Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shanghai Kaibao Pharmaceutical stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥860.80 Million | 17.36% |
| Total Liquid Assets | CN¥860.80 Million | 17.36% |
Asset Resilience Insights
- Good Liquidity Position: Shanghai Kaibao Pharmaceutical maintains a healthy 17.36% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Kaibao Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Shanghai Kaibao Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for Shanghai Kaibao Pharmaceutical (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Kaibao Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.98% | CN¥180.02 Million ≈ $26.34 Million |
CN¥4.52 Billion ≈ $661.19 Million |
+0.71pp |
| 2023-12-31 | 3.28% | CN¥150.01 Million ≈ $21.95 Million |
CN¥4.58 Billion ≈ $670.15 Million |
+0.08pp |
| 2022-12-31 | 3.19% | CN¥136.07 Million ≈ $19.91 Million |
CN¥4.26 Billion ≈ $623.27 Million |
+1.67pp |
| 2021-12-31 | 1.53% | CN¥51.26 Million ≈ $7.50 Million |
CN¥3.36 Billion ≈ $491.06 Million |
-2.46pp |
| 2020-12-31 | 3.98% | CN¥114.65 Million ≈ $16.78 Million |
CN¥2.88 Billion ≈ $421.04 Million |
-13.10pp |
| 2019-12-31 | 17.08% | CN¥485.57 Million ≈ $71.05 Million |
CN¥2.84 Billion ≈ $415.95 Million |
+14.01pp |
| 2018-12-31 | 3.07% | CN¥84.28 Million ≈ $12.33 Million |
CN¥2.75 Billion ≈ $402.03 Million |
-0.79pp |
| 2017-12-31 | 3.86% | CN¥103.38 Million ≈ $15.13 Million |
CN¥2.68 Billion ≈ $392.13 Million |
+2.21pp |
| 2016-12-31 | 1.64% | CN¥41.58 Million ≈ $6.08 Million |
CN¥2.53 Billion ≈ $369.91 Million |
+0.67pp |
| 2015-12-31 | 0.98% | CN¥23.72 Million ≈ $3.47 Million |
CN¥2.43 Billion ≈ $355.10 Million |
-8.00pp |
| 2014-12-31 | 8.97% | CN¥190.00 Million ≈ $27.80 Million |
CN¥2.12 Billion ≈ $309.84 Million |
-- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more